Odontogenic Kerato Cyst / OKC is an odontogenic pathological entity that has created many controversies among surgeons; this might be multi-factorial due to its high recurrence rate, as well as being an essential component of the nevoid basal cell syndrome, and finally, the lack of generalized consensus on how to successfully treat this cyst. In this session, we would like to review the current approaches implemented in treating OKCs while highlighting historical methods and newer treatment modalities that have utilized the understanding of genetic mutation identified in managing this pathological entity. At the end of this session, we would like to share our experience at LSU utilizing our method of incorporating 5-Flurouricel / 5-FU in an easy, cheap way and review our favorable outcomes.
Learning Objectives:
At the conclusion of this presentation, participants should be able to:
Recognize the Genetic mutations of benign odontogenic Keratocysts.
Explain the 2022 WHO H&N classification as it pertains to OKCs & compare it to previous versions of this classification.
Identify the latest criteria for Nevoid Basal cancer syndrome.
Describe historic surgical options and define recurrence rates associated with various treatment modalities.
Incorporate these technique in an academic, hospital or private practice set up.